The promising role of semi-solid extrusion technology in custom drug formulation for pediatric medicine

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
dc.contributor.authorCerveto, Thomas
dc.contributor.authorDenis, Lucas
dc.contributor.authorStoops, Maxime
dc.contributor.authorLechanteur, Anna
dc.contributor.authorJérôme, Christine
dc.contributor.authorLeenhardt, Julien
dc.contributor.authorFlynn,Stephen
dc.contributor.authorGoyanes, Alvaro
dc.contributor.authorMazet, Roseline
dc.contributor.authorAnnereau, Maxime
dc.contributor.authorChoisnard, Luc
dc.date.accessioned2025-12-22T07:52:34Z
dc.date.available2025-12-22T07:52:34Z
dc.date.issued2024-08-29
dc.descriptionThis article belongs to the Special Issue: Advanced Biomaterials for 3D Printing and Healthcare Application. This review was produced as part of the 13th Journée Scientifique du Médicament, organized by the Département de Pharmacochimie Moléculaire (UMR CNRS-UGA 5063) and the Grenoble University Hospital Center (CHUGA). The event, which focused on the 3D printing of medicinal products, was held on June 13, 2024.
dc.description.abstractThe long-standing issue of inadequate medicine formulations has been a focus of regulatory bodies and pharmaceutical research, particularly in adapting medicines for children’s unique requirements. The pediatric population presents diverse challenges in pharmacotherapy due to their varying age-related physiological differences, and taste and dosage form preferences. Conventional formulations often fail to meet these needs, leading to a high prevalence of off-label medication use and modifications by caregivers, which can compromise drug efficacy and safety. The well-known challenges of managing children’s medication are similar to those in geriatrics, both of which require dose adjustments to accommodate the patient’s pathophysiological characteristics and prevent deglutination problems. This paper explores recent innovations in drug formulations, highlighting the shift from traditional liquid formulations to solid dosages through three-dimensional (3D) printing technology. Recent advancements in 3D printing technology offer promising solutions to these challenges. Additive manufacturing (AM), or 3D printing, facilitates the creation of complex objects (e.g., drug formulations) directly from digital models, allowing for high precision and customization. 3D-printed formulations have displayed considerable promise in improving palatability, adherence, and dose accuracy for pediatric use. Innovations like chewable tablets and taste-masked formulations make medications more acceptable to children. Moreover, the ability of 3D printing to adjust drug release profiles and doses offers a personalized approach to pediatric and geriatric pharmacotherapy, which is essential for managing conditions that require precise therapeutic control. The paper discusses several case studies using the semi-solid extrusion (SSE) process for producing personalized dosage forms, along with various technical and regulatory challenges associated with implementing this process in hospital-based drug manufacturing. In conclusion, while 3D printing in pediatric and geriatric pharmacotherapy addresses many challenges of traditional drug formulations, ongoing research and adaptation of regulatory frameworks are necessary to expand its application, ensuring safer, more effective, and more acceptable medication.
dc.description.peerreviewedSI
dc.description.sponsorshipThis work was partially supported by Agence Nationale de la Recherche through Labex ARCANE and CBH-EUR-GS (ANR-17-EURE-0003)
dc.identifier.citationCerveto, T., Denis, L., Stoops, M., Lechanteur, A., Jérôme, C., Leenhardt, J., Flynn, S., Goyanes, A., Mazet, R., Annereau, M., & Choisnard, L. (2024). The promising role of semi-solid extrusion technology in custom drug formulation for pediatric medicine. "International Journal of Bioprinting", 10(6), 4063, 38-66. https://doi.org/10.36922/IJB.4063
dc.identifier.doi10.36922/ijb.4063
dc.identifier.essn2424-8002
dc.identifier.issn2424-7723
dc.identifier.urihttps://hdl.handle.net/10347/44630
dc.issue.number6
dc.journal.titleInternational Journal of Bioprinting
dc.language.isoeng
dc.page.final66
dc.page.initial38
dc.publisherAccScience Publishing
dc.relation.projectIDinfo:eu-repo/grantAgreement/ANR/CBH-EUR-GS/ANR-17-EURE-0003/FR
dc.relation.publisherversionhttps://doi.org/10.36922/ijb.4063
dc.rightsCopyright: © 2024 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectUnlicensed preparation
dc.subject3D printing
dc.subjectPediatrics
dc.subjectSemi-solid extrusion
dc.subjectHospital preparation
dc.subject.classification2390 Química farmacéutica
dc.titleThe promising role of semi-solid extrusion technology in custom drug formulation for pediatric medicine
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2024_bioprinting_goyanes_promising.pdf
Size:
3 MB
Format:
Adobe Portable Document Format